Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


With Incivek Deflated, Vertex’s HCV Roller Coaster Ride Hinges On Phase II Candidate VX-135

This article was originally published in The Pink Sheet Daily

Executive Summary

Along with steep job cuts in the commercial force behind hepatitis C drug Incivek, Vertex is nearing a go/no-go decision on development of Phase II nucleoside polymerase inhibitor VX-135 for HCV. Incivek earned nearly $1 billion in its first 10 months of sales, but fell to $86 million in the third quarter of 2013.


Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts